1) Surgery is the cornerstone of treatment for the majority of low-grade astrocytomas, while postoperative radiotherapy has been shown to lengthen the progression-free period without significantly affecting the overall survival - median survival is 7.
Compared with the differential diagnoses suggested when evaluating the conventional MRI, the multimodal MRI (MRS and/or PWI) provided additional information in 27 (61%) patients and helped to differentiate between lymphoma and GBM in 7 patients (4 GBM and 3 lymphomas); between GBM and metastases in 7 patients; between high-grade and low-grade astrocytomas in 5 patients; between various other tumours in 4 patients; and between tumours and non-neoplastic conditions in 4 patients (Table 3).
A review of the Low-Grade Astrocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of the Low-Grade Astrocytoma pipeline on the basis of route of administration and molecule type.
Duplication of 7q34 in pediatric low-grade astrocytomas
detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene.
The median survival of patients with low-grade astrocytomas
is 5 years, and most patients die from progression of their disease to a high-grade astrocytoma.
They located changes in the IDH1 gene in more than 70 percent of three common types of gliomas: low-grade astrocytomas
, oligodendrogliomas, and secondary glioblastomas.